Skip to main content

Table 1 Characteristics of patients in TDF+PI/r and control groups a

From: Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study

Variable

TDF+PI/r group (n=75)

Control group (n=75)

P

Male

58(77.3)

53(70.7)

0.352

Age (years)

44 (41–50)

42 (34–53)

0.322

Race

  

0.363

  Han

74 (98.7)

71 (94.7)

 

  Other

1 (1.3)

4 (5.3)

 

Duration of HIV seropositive (months)

65 (26–139)

22 (19–28)

<0.001

Smoking

   

  Yes

32(42.7)

27(36.0)

0.403

  No

43(57.3)

48(64.0)

 

Hypertension

  

0.347

  Yes

7(9.3)

4(5.3)

 

  No

68(90.7)

71(94.7)

 

Diabetes

  

0.332

  Yes

4(5.3)

1(1.3)

 

  No

67(89.3)

68(90.7)

 

  Unknown

4(5.3)

6(8.0)

 

BMI b (kg/m 2 )

21.6 (20.1-23.5)

20.6 (19.5-23.0)

0.129

CD4 cell count (cells/μl)

157(63–267)

185 (104–259)

0.509

Viral load (log10 copies/ml)

4.4 (3.7-4.8)

4.5 (3.9-4.9)

0.117

Proteinuria

  

0.631

  Positive

11(14.7)

9 (12)

 

  Negative

64(85.3)

66 (88)

 

Serum creatinine (μmol/L)

71(65–81)

71.4(62–81.7)

0.263

eGFR c (ml/min/1.73 m 2 )

101.6 (85.6-117.2)

105.1 (76.8-110.3)

0.376

  1. Note.
  2. aValues are expressed as median (interquartile range) or number (percentage).
  3. bBMI =weight (kg)/(height (m))2.
  4. ceGFR = 186 × (Serum creatinine (mg/dL))-1.154 × (age(years))-0.203 × (0.742 if female).